TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

MOVA

OncologyCardiovascularRespiratory
Generics

MOVA is a generic drug manufacturer focused on Oncology, Cardiovascular, Respiratory.

1994
Since
1
Drugs
-
Trials
5
Approved (2yr)

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 38%
0 drugs Phase 2: 1 Phase 1: 3
Cardiovascular 31%
0 drugs Phase 2: 2
Respiratory 31%
0 drugs Phase 2: 2

Pipeline Strength Pro

Loading...